Spero Therapeutics (SPRO) Competitors $2.90 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.91 +0.01 (+0.38%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SPRO vs. NUVB, IOVA, ABUS, DAWN, GHRS, SION, STOK, CDXC, XNCR, and KALVShould you be buying Spero Therapeutics stock or one of its competitors? The main competitors of Spero Therapeutics include Nuvation Bio (NUVB), Iovance Biotherapeutics (IOVA), Arbutus Biopharma (ABUS), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), Sionna Therapeutics (SION), Stoke Therapeutics (STOK), ChromaDex (CDXC), Xencor (XNCR), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Spero Therapeutics vs. Its Competitors Nuvation Bio Iovance Biotherapeutics Arbutus Biopharma Day One Biopharmaceuticals GH Research Sionna Therapeutics Stoke Therapeutics ChromaDex Xencor KalVista Pharmaceuticals Nuvation Bio (NYSE:NUVB) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation. Does the media prefer NUVB or SPRO? In the previous week, Nuvation Bio had 1 more articles in the media than Spero Therapeutics. MarketBeat recorded 4 mentions for Nuvation Bio and 3 mentions for Spero Therapeutics. Nuvation Bio's average media sentiment score of 0.65 beat Spero Therapeutics' score of 0.47 indicating that Nuvation Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, NUVB or SPRO? Nuvation Bio has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Which has preferable valuation & earnings, NUVB or SPRO? Spero Therapeutics has higher revenue and earnings than Nuvation Bio. Spero Therapeutics is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M88.85-$567.94M-$2.35-0.87Spero Therapeutics$47.98M3.38-$68.57M-$1.28-2.27 Is NUVB or SPRO more profitable? Spero Therapeutics has a net margin of -156.48% compared to Nuvation Bio's net margin of -5,534.21%. Nuvation Bio's return on equity of -44.14% beat Spero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-5,534.21% -44.14% -32.97% Spero Therapeutics -156.48%-123.50%-58.96% Do analysts recommend NUVB or SPRO? Nuvation Bio currently has a consensus price target of $7.17, indicating a potential upside of 248.74%. Spero Therapeutics has a consensus price target of $5.00, indicating a potential upside of 72.41%. Given Nuvation Bio's stronger consensus rating and higher possible upside, research analysts plainly believe Nuvation Bio is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals hold more shares of NUVB or SPRO? 61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 29.9% of Nuvation Bio shares are held by company insiders. Comparatively, 5.5% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryNuvation Bio beats Spero Therapeutics on 12 of the 16 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition Export to ExcelMetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$162.14M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-2.2721.3126.1719.90Price / Sales3.38278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book3.417.518.055.38Net Income-$68.57M-$55.05M$3.15B$248.50M7 Day PerformanceN/A2.45%1.85%2.97%1 Month Performance5.84%7.33%4.81%6.02%1 Year Performance122.22%5.38%34.86%20.39% Spero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics4.2914 of 5 stars$2.90flat$5.00+72.4%+126.6%$162.14M$47.98M-2.27150NUVBNuvation Bio3.4764 of 5 stars$2.02+2.3%$7.17+255.7%-38.7%$670.32M$7.87M-0.8660High Trading VolumeIOVAIovance Biotherapeutics4.7042 of 5 stars$1.85-6.6%$12.22+560.7%-78.4%$661.19M$164.07M-1.49500ABUSArbutus Biopharma1.9235 of 5 stars$3.41-0.6%$5.50+61.3%+1.9%$656.94M$6.17M-8.3290DAWNDay One Biopharmaceuticals2.1421 of 5 stars$6.48+2.5%$30.57+371.8%-51.3%$640.61M$131.16M-9.1360Upcoming EarningsGHRSGH Research1.9222 of 5 stars$11.68-5.1%$32.00+174.0%+8.3%$640.47MN/A-14.7810News CoverageSIONSionna TherapeuticsN/A$14.10-2.7%$38.50+173.0%N/A$639.36MN/A0.0035News CoveragePositive NewsInsider TradeGap UpSTOKStoke Therapeutics4.0242 of 5 stars$11.59+0.1%$23.20+100.2%-16.0%$632.23M$36.56M14.67100Analyst ForecastCDXCChromaDex3.1841 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120XNCRXencor4.0421 of 5 stars$8.41-1.5%$28.00+232.9%-57.6%$607.80M$110.49M-2.75280KALVKalVista Pharmaceuticals4.2788 of 5 stars$11.93-1.8%$24.83+108.2%-2.5%$604.04MN/A-3.21100 Related Companies and Tools Related Companies Nuvation Bio Alternatives Iovance Biotherapeutics Alternatives Arbutus Biopharma Alternatives Day One Biopharmaceuticals Alternatives GH Research Alternatives Sionna Therapeutics Alternatives Stoke Therapeutics Alternatives ChromaDex Alternatives Xencor Alternatives KalVista Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRO Stock Alerts